BoneSupport today announced plans to expand its sales force, adding an additional 13 sales representatives in “key markets” this year.
The Swedish company said that the objective of the expansion is to increase the market penetration of its antibiotic-eluting Cerament G and Cerament V products.
BoneSupport touted that in April, three studies of its Cerament platform were presented at the British Limb Reconstruction Society meeting, some of which showed improved bone healing and reduced risk of recurrent infections with the use of the Cerament G product.
“Cerament G and V have strong sales momentum in Europe due to their increased use in a wide range of orthopedic indications. The adoption level is particularly high in osteomyelitis, a challenging indication that generally requires repeated surgical interventions. We see significant commercial potential for Cerament G and V in multiple important treatment areas, including the much larger trauma indication. Today’s decision to almost double the number of sales specialists in Europe, reflects the sizeable opportunity we see for our Cerament products across the region in indications where we have so far had a relatively low level of penetration,” CEO Emil Billbäck said in a press release.